{"product_id":"stem-cell-transplants-for-multiple-myeloma-what-a-10-year-european-study-reveals-about-combining-your-own-cells-with-a-donors-cells-vs-using-your-own-cells-alone","title":"Stem Cell Transplants for Multiple Myeloma: What a 10-Year European Study Reveals About Combining Your Own Cells With a Donor's Cells vs. Using Your Own Cells Alone","description":"\u003cp\u003eThis long-term study compared two stem-cell transplant strategies for patients with previously untreated multiple myeloma: a tandem approach combining high-dose chemotherapy with autologous (own) stem-cell transplant followed by a reduced-intensity allogeneic (donor) transplant, versus autologous transplant alone. Following 357 patients for a median of 61 months, researchers found that the auto-allo approach produced significantly better progression-free survival (35% vs. 18% at 60 months), a lower relapse rate (49% vs. 78%), and improved long-term overall survival (65% vs. 58%). While transplant-related mortality was higher in the auto-allo group (12% vs. 3% at 24 months), the study concludes that the long-term disease control benefits of the tandem approach outweigh the added risks for many patients.\u003c\/p\u003e\n\n\u003ch1\u003eStem Cell Transplants for Multiple Myeloma: What a 10-Year European Study Reveals About Combining Your Own Cells With a Donor's Cells vs. Using Your Own Cells Alone\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding the Research: Why This Study Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: What the Results Showed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#chromosome\"\u003ePatients With High-Risk Chromosome Changes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#per-protocol\"\u003eComparing Patients Who Actually Received Their Full Treatment Plan\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#gvhd\"\u003eGraft-Versus-Host Disease: A Key Side Effect of Donor Transplants\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eQuestions to Discuss With Your Doctor\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a 357-patient European study, five-year progression-free survival was 35% with auto-allo transplant versus 18% with autologous transplant alone.\u003c\/li\u003e\n\u003cli\u003eAt five years, relapse occurred in 49% of the auto-allo group versus 78% of the autologous-only group.\u003c\/li\u003e\n\u003cli\u003eFive-year overall survival was 65% with auto-allo versus 58% with autologous transplant alone.\u003c\/li\u003e\n\u003cli\u003eNonrelapse mortality was higher with auto-allo: 12% versus 3% at two years.\u003c\/li\u003e\n\u003cli\u003eThe study was not randomized and used older treatments, so current risks and benefits may differ.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding the Research: Why This Study Matters\u003c\/h2\u003e\n\n\u003cp\u003eMultiple myeloma is a cancer of plasma cells, a type of white blood cell that normally helps fight infections. Despite significant advances in treatment, myeloma is still considered an incurable disease, although some patients do achieve long-lasting remissions, especially after intensive high-dose chemotherapy. For adults up to about age 65, high-dose therapy followed by an \u003cstrong\u003eautologous stem-cell transplant (ASCT)\u003c\/strong\u003e — a procedure where a patient's own blood-forming stem cells are collected, stored, and returned after high-dose chemotherapy — has become part of the standard first-line treatment plan.\u003c\/p\u003e\n\n\u003cp\u003eThere is another type of transplant, called an \u003cstrong\u003eallogeneic stem-cell transplant (alloSCT)\u003c\/strong\u003e, where stem cells come from a donor. When this approach was first tried in the mid-1980s using very intensive (myeloablative) conditioning, it showed promise because of a unique \"graft-versus-myeloma\" effect, where the donor's immune cells attack the cancer. However, this older method was hampered by severe toxicity and a very high rate of treatment-related death, ranging from 30% to 50% in some studies. In fact, one case-control trial found that patients actually did better with their own stem cells than with a myeloablative donor transplant, despite the donor approach having a lower relapse rate.\u003c\/p\u003e\n\n\u003cp\u003eThe development of \u003cstrong\u003ereduced-intensity conditioning (RIC)\u003c\/strong\u003e changed the picture. This gentler approach uses lower doses of radiation and chemotherapy, making the transplant safer. When high-dose chemotherapy with autologous transplant was combined with a subsequent reduced-intensity allogeneic transplant (called auto-allo), the treatment-related death rate dropped to 15% or less. The question remained, however: is this tandem auto-allo approach actually better than the \"gold standard\" autologous transplant alone? Earlier smaller studies had produced conflicting results.\u003c\/p\u003e\n\n\u003cp\u003eThis study was designed to answer that question in a large group of patients with newly diagnosed myeloma, with a long follow-up period to see whether the benefits — and risks — held up over time. The results were published in the \u003cem\u003eJournal of Clinical Oncology\u003c\/em\u003e, one of the most respected peer-reviewed journals in cancer medicine.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003ch3\u003eWho Was Included?\u003c\/h3\u003e\n\u003cp\u003eFrom February 2001 through January 2005, a total of \u003cstrong\u003e357 patients with multiple myeloma, up to age 69 years\u003c\/strong\u003e, were enrolled at 23 European Bone Marrow Transplantation (EBMT) centers. To be eligible, patients had to have achieved at least stable disease on their first-line (initial) treatment. This included those in \u003cstrong\u003ecomplete response (CR)\u003c\/strong\u003e — meaning no detectable cancer; \u003cstrong\u003epartial remission (PR)\u003c\/strong\u003e — meaning significant reduction in cancer; or \u003cstrong\u003estable disease (SD)\u003c\/strong\u003e — meaning the cancer hadn't grown. All patients had undergone HLA typing, a blood test that determines tissue compatibility for transplantation.\u003c\/p\u003e\n\n\u003cp\u003eA key point is how patients were assigned to treatment groups. This was not a \"randomized\" trial in the traditional sense, where patients are randomly assigned by a computer. Instead:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e108 patients\u003c\/strong\u003e who had an HLA-identical sibling (a brother or sister with matching tissue type) were assigned to the \u003cstrong\u003eauto-allo arm\u003c\/strong\u003e (autologous transplant followed by reduced-intensity donor transplant)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e249 patients\u003c\/strong\u003e without a matched sibling were assigned to the \u003cstrong\u003eauto arm\u003c\/strong\u003e (autologous transplant alone)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eInterestingly, two patients in the auto-allo arm actually had a sibling donor with one HLA mismatch, not a perfect match, and were mistakenly treated on the auto-allo protocol. In keeping with standard statistical practice, they were still included in the auto-allo group in what's called an \u003cstrong\u003eintention-to-treat (ITT) analysis\u003c\/strong\u003e — meaning patients are analyzed in the group they were assigned to, regardless of whether they received exactly the planned treatment.\u003c\/p\u003e\n\n\u003cp\u003eThe time point for enrolling in the trial was at the time of the first autologous transplant, after completion of induction treatment. Patients could have either a single autologous transplant or a tandem (double) autologous transplant — this was left to each study center's discretion. Patients with substantial kidney failure (glomerular filtration rate below 50 mL\/min), significant liver impairment (bilirubin more than 2 times the upper limit of normal), severe heart failure (left ventricular ejection fraction below 40%), or major dysfunction of other organ systems were excluded from the study.\u003c\/p\u003e\n\n\u003cp\u003eBaseline characteristics were evenly balanced between the two groups, with one notable exception: age at diagnosis. The auto group was slightly older, with a median age of 57 years, compared with 54 years in the auto-allo group. The median follow-up time from the first transplant was \u003cstrong\u003e61 months (approximately 5 years)\u003c\/strong\u003e, with a range of 21 to 91 months, for patients alive at their last follow-up visit.\u003c\/p\u003e\n\n\u003ch3\u003eWhat Treatments Did Patients Receive?\u003c\/h3\u003e\n\u003cp\u003eAll patients received induction chemotherapy before the transplant. The most common regimen was \u003cstrong\u003eVAD\u003c\/strong\u003e, which stands for vincristine, doxorubicin, and dexamethasone. VAD was used in 73% of patients in the auto-allo arm and 67% in the auto arm. The remaining patients received a variety of other regimens, mostly based on cyclophosphamide or dexamethasone. Importantly, no patients in this study were treated with newer \"novel\" drugs such as thalidomide, lenalidomide, or bortezomib, which have since become standard in myeloma treatment — this reflects the era when the study was conducted (2001–2005).\u003c\/p\u003e\n\n\u003cp\u003eAll 357 patients received high-dose chemotherapy with \u003cstrong\u003emelphalan at a dose of 200 mg\/m²\u003c\/strong\u003e, followed by an infusion of their own collected stem cells. Supportive care (medications to prevent infections, growth factors to boost blood counts, and similar measures) was given according to each center's usual routines.\u003c\/p\u003e\n\n\u003cp\u003eOf the 108 patients assigned to the auto-allo arm, \u003cstrong\u003e91 actually received the reduced-intensity allogeneic transplant\u003c\/strong\u003e according to the protocol. The remaining 17 did not receive their planned donor transplant for these specific reasons:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e7 patients\u003c\/strong\u003e had disease progression before the second transplant\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4 patients\u003c\/strong\u003e declined the transplant\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1 patient\u003c\/strong\u003e died before the allogeneic transplant could be done\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1 patient\u003c\/strong\u003e developed kidney failure\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1 patient\u003c\/strong\u003e had failure to collect donor stem cells\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3 patients\u003c\/strong\u003e had a donor who became ill or unavailable; in one of these cases where the donor declined, the patient received a transplant from a matched unrelated donor instead\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAll 17 of these patients were still included in the auto-allo group for the intention-to-treat analysis. The median time between the autologous transplant and the allogeneic (donor) transplant was \u003cstrong\u003e4.2 months\u003c\/strong\u003e, with a range of 1.3 to 22.2 months.\u003c\/p\u003e\n\n\u003cp\u003eThe reduced-intensity conditioning (gentle prep) regimen for the donor transplant consisted of \u003cstrong\u003efludarabine 30 mg\/m² per day for 3 days plus total-body irradiation (TBI) at a low dose of 2 Gy\u003c\/strong\u003e, given in one session. To prevent \u003cstrong\u003egraft-versus-host disease (GvHD)\u003c\/strong\u003e — a condition where the donor's immune cells attack the patient's body — patients received cyclosporine (6.5 mg\/kg taken by mouth twice a day, or 1.5 mg\/kg by vein twice a day, starting from day −1 until it could be taken orally) plus mycophenolate mofetil (15 mg\/kg by mouth twice a day, from day 0 through day 24).\u003c\/p\u003e\n\n\u003cp\u003ePatients in the auto-only group who had no matched sibling donor received either no further treatment (145 patients) or, at their center's discretion, underwent a second autologous transplant as part of a tandem transplantation program (104 patients). The conditioning for that second autograft was the same as the first: melphalan 200 mg\/m². After any allogeneic transplant, further treatment was optional.\u003c\/p\u003e\n\n\u003ch3\u003eHow Were Outcomes Measured?\u003c\/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003eprimary end point\u003c\/strong\u003e (main outcome being measured) was \u003cstrong\u003eprogression-free survival (PFS)\u003c\/strong\u003e — the length of time a patient lives without the cancer growing or returning, measured from the date of enrollment in the study (the date of the first autologous transplant). \u003cstrong\u003eSecondary end points\u003c\/strong\u003e included overall survival (OS), relapse rate, complete remission (CR) rate, and the incidence of nonrelapse mortality (NRM) — that is, death from causes other than the myeloma itself, such as complications of the transplant.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers used sophisticated statistical methods. Because the risk patterns changed over time (the curves \"crossed\" early on, meaning one group could have worse outcomes initially but better outcomes later), standard survival analysis had to be adjusted. They used models with time-varying effects, adjusted for age, and performed \u003cstrong\u003elandmark log-rank tests\u003c\/strong\u003e to assess differences in the long term (after 2 years for most outcomes, and after 3 years for overall survival). The main analysis followed the intention-to-treat principle. Additionally, an exploratory ITT analysis was done in two subgroups based on whether a specific chromosomal abnormality was present, and outcomes were also compared in a per-protocol analysis that included only patients who actually received the planned second transplant type (91 auto-allo patients vs. 104 tandem auto patients).\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: What the Results Showed\u003c\/h2\u003e\n\n\u003ch3\u003eProgression-Free Survival: A Clear Advantage for the Tandem Approach\u003c\/h3\u003e\n\u003cp\u003eAt 60 months (5 years) after the first autologous transplant, \u003cstrong\u003eprogression-free survival was significantly better in the auto-allo group: 35% compared with just 18% in the auto-only group (P = .001)\u003c\/strong\u003e. In plain terms, this means patients who received the tandem auto-allo approach were roughly twice as likely to be alive without their myeloma returning at the 5-year mark. The benefit for the auto-allo group began to emerge after about 2 years of follow-up, corresponding to a significantly lower risk of relapse or disease progression (P = .003).\u003c\/p\u003e\n\n\u003ch3\u003eRelapse Rates: Dramatic Difference\u003c\/h3\u003e\n\u003cp\u003eAt 60 months, the incidence of relapse or disease progression was \u003cstrong\u003e49% in the auto-allo group versus 78% in the auto group\u003c\/strong\u003e — a difference of nearly 30 percentage points. This is one of the most striking findings of the study and directly illustrates the power of the \"graft-versus-myeloma\" effect, where the donor's immune system actively works to eliminate the cancer cells.\u003c\/p\u003e\n\n\u003ch3\u003eOverall Survival: Better Long-Term Results\u003c\/h3\u003e\n\u003cp\u003eLong-term overall survival was also significantly superior in the auto-allo group. The auto-allo group showed a significant reduction in the risk of death over time (P = .006), with a significantly lower risk of death after the 3-year mark (P = .047). At 60 months, \u003cstrong\u003eoverall survival was 65% in the auto-allo group compared with 58% in the auto group\u003c\/strong\u003e. While these numbers may look somewhat close, the statistical analysis confirms the difference was meaningful, particularly as time went on.\u003c\/p\u003e\n\n\u003ch3\u003eComplete Remission Rates: Higher With Auto-Allo\u003c\/h3\u003e\n\u003cp\u003eComplete remission — the disappearance of all detectable signs of cancer — was achieved more often with the tandem approach. \u003cstrong\u003eThe CR rate within 60 months was 51% in the auto-allo group versus 41% in the auto group (P = .020)\u003c\/strong\u003e. For patients who did not achieve CR, the best response status differed as well:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePartial response: 43% (auto-allo) vs. 50% (auto)\u003c\/li\u003e\n  \u003cli\u003eNo response: 3% (auto-allo) vs. 5% (auto)\u003c\/li\u003e\n  \u003cli\u003eProgressive disease: 3% (auto-allo) vs. 4% (auto)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eNonrelapse Mortality: The Price of the Tandem Approach\u003c\/h3\u003e\n\u003cp\u003eNonrelapse mortality — death caused by the transplant itself rather than by the myeloma — was higher in the auto-allo group, as might be expected with a more intensive treatment. The \u003cstrong\u003ecumulative NRM at 24 months was 12% after auto-allo versus 3% in the auto group (P \u0026lt; .001)\u003c\/strong\u003e. At 60 months, the figures were 16% and 4%, respectively. In other words, while the donor transplant approach led to fewer deaths from myeloma, it caused more deaths from transplant complications. The \"balancing act\" between these competing risks is a central theme in interpreting this study.\u003c\/p\u003e\n\n\u003ch2 id=\"chromosome\"\u003ePatients With High-Risk Chromosome Changes\u003c\/h2\u003e\n\n\u003cp\u003eA particularly important aspect of this study was the analysis of patients with a specific chromosomal abnormality known as \u003cstrong\u003edeletion of chromosome 13 — del(13q14)\u003c\/strong\u003e, which has historically been associated with a poorer prognosis in myeloma. Cytogenetic analysis was performed in 214 patients using fluorescent in situ hybridization (FISH), a technique that allows scientists to see specific genetic changes within cells.\u003c\/p\u003e\n\n\u003cp\u003eOf the 214 patients tested:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e92 patients\u003c\/strong\u003e had the del(13) abnormality (29 in the auto-allo group, 63 in the auto group)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e122 patients\u003c\/strong\u003e were negative for del(13) (34 in the auto-allo group, 88 in the auto group)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eFindings in Patients With del(13)\u003c\/h3\u003e\n\u003cp\u003eFor patients with this high-risk chromosome deletion, the benefit of the tandem approach was especially pronounced:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eProgression-free survival at 60 months: 31% with auto-allo vs. 11% with auto (P = .002)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall survival at 60 months: 69% with auto-allo vs. 55% with auto (P = .003)\u003c\/strong\u003e — a striking 14-percentage-point improvement\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRelapse\/progression risk after 2 years:\u003c\/strong\u003e significantly lower in the auto-allo group (P = .004); at 60 months, the relapse rate was \u003cstrong\u003e55% vs. 86%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese numbers suggest that patients with the del(13) abnormality — a group often considered to have harder-to-treat disease — derived substantial benefit from the donor immune cells' anti-myeloma effect.\u003c\/p\u003e\n\n\u003ch3\u003eFindings in Patients Without del(13)\u003c\/h3\u003e\n\u003cp\u003eFor patients negative for del(13), the results also favored the auto-allo approach, though the differences were somewhat smaller:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eProgression-free survival at 60 months: 44% vs. 20% (P = .017)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall survival at 60 months: 70% vs. 61% (P = .363)\u003c\/strong\u003e — not statistically significant in this subgroup\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRelapse\/progression rate:\u003c\/strong\u003e 39% vs. 76% (P = .005 for the hazard after 2 years)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers noted that a tendency toward better outcome was found in both the del(13) and non-del(13) patient groups, which supports and corroborates the findings seen in the overall study population. In other words, the benefit of the tandem approach was broad-based, not limited to one genetic subgroup.\u003c\/p\u003e\n\n\u003ch2 id=\"per-protocol\"\u003eComparing Patients Who Actually Received Their Full Treatment Plan\u003c\/h2\u003e\n\n\u003cp\u003eTo get a cleaner picture of the true effect of the two treatment strategies, the researchers performed a \"per-protocol\" analysis, comparing the \u003cstrong\u003e91 patients who actually received their planned reduced-intensity donor transplant\u003c\/strong\u003e with the \u003cstrong\u003e104 patients who received a second autologous transplant\u003c\/strong\u003e as part of a planned tandem program. This analysis measured outcomes from the time of the second transplant:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eProgression-free survival at 60 months: 39% (auto-allo) vs. 19% (tandem auto) (P = .004)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall survival at 60 months: 63% vs. 60% (P = .753)\u003c\/strong\u003e — but with a highly significant trend of reduction in risk over time (P \u0026lt; .001)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRelapse\/progression rate:\u003c\/strong\u003e 43% vs. 78% (P = .001 for the hazard after 2 years)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eComplete remission rate within 60 months: 56% vs. 44% (P = .007)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eNonrelapse mortality at 60 months: 18% vs. 3% (P \u0026lt; .001)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor patients who did not achieve complete remission in this per-protocol analysis, the best response status was partial response in 35% (auto-allo) vs. 51% (auto), no response in 6% vs. 3%, and progressive disease in 3% vs. 2%.\u003c\/p\u003e\n\n\u003cp\u003eThis analysis reinforces the main findings: the auto-allo approach produced roughly double the progression-free survival and drastically lower relapse rates, at the cost of a higher nonrelapse mortality rate. The overall survival difference was less dramatic early on, but the trend over time strongly favored the donor transplant group.\u003c\/p\u003e\n\n\u003ch2 id=\"gvhd\"\u003eGraft-Versus-Host Disease: A Key Side Effect of Donor Transplants\u003c\/h2\u003e\n\n\u003cp\u003eAmong the 91 patients who actually received the reduced-intensity donor transplant, graft-versus-host disease was a significant concern. GvHD occurs when the donor's immune cells (the graft) recognize the patient's body (the host) as foreign and attack healthy tissues. It can affect the skin, liver, gastrointestinal tract, and other organs, and it can range from mild to life-threatening.\u003c\/p\u003e\n\n\u003ch3\u003eAcute GvHD (occurring early, usually within the first 100 days)\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade 1:\u003c\/strong\u003e occurred in 10 patients (11%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade 2:\u003c\/strong\u003e occurred in 8 patients (9%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade 3:\u003c\/strong\u003e occurred in 8 patients (9%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade 4:\u003c\/strong\u003e occurred in 2 patients (2%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo acute GvHD at all:\u003c\/strong\u003e 60 patients (67%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn total, the incidence of grade 2 to 4 acute GvHD was \u003cstrong\u003e20%\u003c\/strong\u003e — meaning one in five patients experienced a moderate to severe early immune reaction. This aligns with what's expected for reduced-intensity conditioning transplants in myeloma patients.\u003c\/p\u003e\n\n\u003ch3\u003eChronic GvHD (occurring later, often after day 100)\u003c\/h3\u003e\n\u003cp\u003eA total of \u003cstrong\u003e49 patients (54%)\u003c\/strong\u003e developed chronic GvHD. This was classified as:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited chronic GvHD:\u003c\/strong\u003e 28 patients (31%) — typically affecting only the skin or a single organ\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExtensive chronic GvHD:\u003c\/strong\u003e 21 patients (23%) — involving multiple organs or more severe manifestations\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eChronic GvHD can significantly affect quality of life, requiring ongoing immunosuppressive treatment. However, it's worth noting that the presence of GvHD is also often associated with a stronger graft-versus-myeloma effect, which may partially explain the lower relapse rates seen in the auto-allo group. This is sometimes called the \"graft-versus-leukemia\/lymphoma\/graft-versus-tumor\" trade-off: some GvHD may be a marker that the donor immune cells are actively working, but too much can be harmful.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study provides important, long-term evidence about treatment strategies for multiple myeloma. Here's how to make sense of the results:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe tandem auto-allo approach offers dramatically better disease control.\u003c\/strong\u003e The relapse rate at 5 years was 49% with auto-allo compared with 78% with auto alone — a massive difference. Progression-free survival was nearly doubled (35% vs. 18%). For patients who are candidates for this approach, the chance of staying in remission longer without the myeloma coming back is substantially higher.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe survival benefit grows with time.\u003c\/strong\u003e While overall survival at 5 years was 65% vs. 58%, the statistical analysis showed that the survival advantage of auto-allo strengthened over time, particularly after the 3-year mark. This suggests the benefit is durable and not just an early effect.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBut there's a real trade-off.\u003c\/strong\u003e The nonrelapse mortality was 12% at 2 years in the auto-allo group vs. 3% in the auto group. This means that some patients in the donor transplant group died from transplant complications, including GvHD and infections. For every 100 patients treated with the auto-allo approach, roughly 9 to 12 additional deaths from transplant-related causes occurred compared with the auto-only approach. However, these early risks were counterbalanced by many fewer deaths from myeloma over the long run.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-risk patients may benefit most.\u003c\/strong\u003e Patients with the del(13) chromosomal abnormality — often considered a poor-prognosis marker — showed especially large benefits from the tandem approach: overall survival at 5 years was 69% vs. 55%. This suggests that the donor immune effect may be particularly valuable in patients whose disease is otherwise harder to control.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThis study reflects an older treatment era.\u003c\/strong\u003e None of the patients received novel agents like thalidomide, lenalidomide, or bortezomib, which are now standard in first-line myeloma therapy. Modern regimens incorporating these drugs may alter the risk-benefit calculus. Patients today might have better outcomes with either approach, and the comparison could differ with newer treatments. Additionally, the study enrolled patients from 2001 to 2005, so supportive care and transplant techniques have improved since then.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eUnderstanding the limitations of this study is crucial for interpreting the results appropriately:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot a randomized trial.\u003c\/strong\u003e Patients were assigned to treatment groups based on whether they had a matched sibling donor. This creates the possibility of \"selection bias\" — the two groups might differ in ways beyond just the treatment received. The authors note that age was slightly different (median 54 vs. 57 years), but other factors — including general health, fitness for transplantation, and unmeasured variables — could also have differed. Having a sibling donor can be associated with socioeconomic and family factors that could influence outcomes. The researchers adjusted for age in their statistical models, but as with any nonrandomized study, residual confounding is possible.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited to a specific era of treatment.\u003c\/strong\u003e No patients received modern agents like thalidomide, lenalidomide, or bortezomib, and the conditioning regimens and supportive care reflect 2001–2005 practices. Results may not fully apply to patients treated with today's standard protocols.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRelatively small subgroups.\u003c\/strong\u003e The cytogenetic subgroup analyses were exploratory, and the confidence intervals around the estimates were wide. For instance, in the non-del(13) subgroup, the overall survival difference was not statistically significant (P = .363).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDonor availability as a selection criterion.\u003c\/strong\u003e The fact that the auto-allo group all had siblings who were HLA-identical could introduce bias — these patients were \"selected\" by a biological availability factor that could correlate with other characteristics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment modifications.\u003c\/strong\u003e Seventeen patients in the auto-allo arm (16%) didn't receive their planned allogeneic transplant. While the intention-to-treat analysis handles this appropriately for statistical purposes, it also means the \"real-world\" application of the auto-allo plan can be disrupted by disease progression or other complications before the second transplant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGenetic testing only for del(13).\u003c\/strong\u003e The study didn't incorporate other important high-risk markers now known to affect myeloma prognosis, such as chromosome 17p deletions, translocations like t(4;14) or t(14;16), or the more recent gene expression profiling that's often used in modern practice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eQuestions to Discuss With Your Doctor\u003c\/h2\u003e\n\n\u003cp\u003eBased on this research and its implications, here are some important questions patients with multiple myeloma (or their family members) may want to discuss with their oncology team:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAm I a candidate for a tandem auto-allo transplant?\u003c\/strong\u003e Factors like your age, overall health, organ function, and availability of a matched donor (sibling or unrelated) all matter. The study specifically included patients up to age 69 with adequate organ function.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat is my cytogenetic (chromosome) risk profile?\u003c\/strong\u003e The results suggest that patients with high-risk features like del(13) may derive particularly large benefits from the donor transplant approach. Ask what testing has been done and how it affects your treatment recommendations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat are my personal risks of transplant-related complications?\u003c\/strong\u003e Nonrelapse mortality at 2 years was about 12% in the auto-allo group vs. 3% in the auto group. Your doctor can help assess how your individual health status (heart, kidney, liver function, age, fitness) might shift these risks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHow do modern drugs change the equation?\u003c\/strong\u003e This study was conducted before thalidomide, lenalidomide, bortezomib, and carfilzomib became routine. Ask how your planned treatment, including any novel agents, might interact with or modify the transplant strategy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat would my quality of life look like?\u003c\/strong\u003e Chronic GvHD occurred in over half of the auto-allo patients (54%), which can require long-term immunosuppression and can impact daily life. Discuss what supportive care measures would be in place and how GvHD would be managed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat's the timing?\u003c\/strong\u003e In this study, the median interval between the autologous and allogeneic transplant was about 4 months. Ask about the recommended timeline for your own treatment plan.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe decision between an autologous transplant alone versus a tandem auto-allo approach is deeply personal and depends on a careful weighing of risks and benefits. For some patients — particularly those with high-risk disease, a good performance status, and a suitable donor — the substantially lower relapse rate and better long-term survival may clearly justify the higher early transplant-related risks. For others, particularly those with significant coexisting health conditions, the auto-only approach may represent the safer, more appropriate choice.\u003c\/p\u003e\n\n\u003cp\u003eWhat makes this study valuable is its size (357 patients), its long follow-up (median 61 months), and its comprehensive reporting of both benefits (improved PFS, OS, relapse rates) and harms (increased NRM and GvHD). It provides patients and doctors with realistic, evidence-based information to make shared treatment decisions.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are the two transplant strategies for multiple myeloma compared here?\u003c\/h3\u003e\n\u003cp\u003eOne is high-dose chemotherapy followed by an autologous transplant using your own collected stem cells. The other, called auto-allo, adds a later reduced-intensity donor transplant. In a study of 357 patients, the auto-allo approach roughly doubled the chance of being alive without the myeloma returning at five years, but carried higher early risks.\u003c\/p\u003e\n\u003ch3\u003eWho could participate in this transplant study?\u003c\/h3\u003e\n\u003cp\u003ePatients were up to age 69 with newly diagnosed multiple myeloma and had to have at least stable disease after first-line chemotherapy. All had adequate organ function and HLA typing. Those with a matched sibling were assigned to the auto-allo approach; those without received an autologous transplant alone. This was not a randomized trial.\u003c\/p\u003e\n\u003ch3\u003eHow much better was progression-free survival with the tandem auto-allo approach?\u003c\/h3\u003e\n\u003cp\u003eAt five years, progression-free survival was 35% with auto-allo versus 18% with autologous transplant alone. That means patients in the donor transplant group were roughly twice as likely to be alive without myeloma recurrence at that point, based on 357 patients followed for a median of 61 months.\u003c\/p\u003e\n\u003ch3\u003eWhat were the main risks of the auto-allo transplant approach?\u003c\/h3\u003e\n\u003cp\u003eThe donor transplant caused more treatment-related deaths and graft-versus-host disease. At two years, nonrelapse mortality was 12% with auto-allo versus 3% with autologous transplant alone. Chronic GvHD affected 54% of patients who actually received the donor transplant. However, fewer patients in the auto-allo group died from myeloma over the long term.\u003c\/p\u003e\n\u003ch3\u003eAre these results still relevant with modern myeloma drugs?\u003c\/h3\u003e\n\u003cp\u003eThis study treated patients from 2001 to 2005, before drugs like thalidomide, lenalidomide, and bortezomib were standard. Modern treatments may improve outcomes with either approach. Also, the study was not randomized, so results may not fully apply to today's protocols. Discuss with your oncology team how newer therapies change the balance.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion on choosing a tandem auto-allo stem cell transplant versus an autologous transplant alone for multiple myeloma?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth considering if your treatment team recommends one strategy but you want a deeper look at the trade-offs. In a 357-patient European study with a median 61-month follow-up, the tandem auto-allo approach roughly doubled 5-year progression-free survival (35% vs. 18%) and cut relapse rates (49% vs. 78%), but raised nonrelapse mortality at 2 years (12% vs. 3%). Benefit appeared largest in patients with the del(13) high-risk change. Because assignment was based on donor availability rather than randomization, another expert can help you weigh these risks and benefits. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Tandem Autologous Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma  Long-Term Follow-Up   Journal of Clinical Oncology\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Bo Björkstrand, Simona Iacobelli, Ute Hegenbart, Astrid Gruber, Hildegard Greinix, Liisa Volin, Franco Narni, and Gösta Gahrton (with additional contributors)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e \u003cem\u003eJournal of Clinical Oncology\u003c\/em\u003e, July 05, 2011, Volume 29, Issue 22, pages 3016–3022\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1200\/JCO.2010.32.7312\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStudy Registration:\u003c\/strong\u003e The trial was conducted across 23 European Bone Marrow Transplantation (EBMT) centers, enrolling patients from February 2001 through January 2005.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and is not a substitute for individualized medical advice from a qualified health care professional. Treatment decisions should always be made in consultation with your oncology team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47549358604444,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/zh\/products\/stem-cell-transplants-for-multiple-myeloma-what-a-10-year-european-study-reveals-about-combining-your-own-cells-with-a-donors-cells-vs-using-your-own-cells-alone","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}